NCT05053971 - Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 16, 2022

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2026

Conditions

Advanced LymphomaAdvanced Malignant Solid NeoplasmAdvanced Pancreatic CarcinomaB-Cell Non-Hodgkin LymphomaMetastatic Pancreatic CarcinomaRefractory B-Cell Non-Hodgkin LymphomaRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Pancreatic CarcinomaRefractory T-Cell Non-Hodgkin LymphomaStage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Pancreatic Carcinoma

Interventions

DRUG

BET Bromodomain Inhibitor ZEN-3694

Given PO

PROCEDURE

Core Biopsy

Undergo core needle biopsy

DRUG

Entinostat

Given PO

Trial Locations (3)

32610

RECRUITING

University of Florida Health Science Center - Gainesville, Gainesville

73104

RECRUITING

University of Oklahoma Health Sciences Center, Oklahoma City

06520

RECRUITING

Yale University, New Haven

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH